Warning letterPosted July 7, 2026
FDA warning letter to LyfeUnit / www.lyfeunit.com
Unapproved New Drugs/Misbranded
FDA posted a warning letter to LyfeUnit / www.lyfeunit.com on July 7, 2026; the letter is dated June 23, 2026. Subject: Unapproved New Drugs/Misbranded. Issuing office: Center for Drug Evaluation and Research (CDER).
On the record
- Company
- LyfeUnit / www.lyfeunit.com
- Subject
- Unapproved New Drugs/Misbranded
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Letter dated
- 2026-06-23
- Posted by FDA
- 2026-07-07
- Source
- FDA warning letters ↗
CFR cited
The record cites 2 sections of 21 CFR Part 201.
The full record
An account shows the violations FDA described and each CFR section it cited.
What a warning letter is
A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.
More
Watch LyfeUnit / www.lyfeunit.com
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA warning letters. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with LyfeUnit / www.lyfeunit.com.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.